专业监测看板

To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

药物 / 成分：Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly、Batoclimab 340 mg SC weekly、Placebo

登记的停止原因（原文）：Sponsor Decision

Study of ExoFlo for the Treatment of Perianal Fistulas

药物 / 成分：ExoFlo、Local injection of normal saline

登记的停止原因（原文）：Enrollment challenges.

A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

药物 / 成分：Placebo、PF-06823859

登记的停止原因（原文）：Pfizer has made an internal business decision to not continue this study. This decision was not due to safety concerns or clinical effect reasons or requests from any regulatory authorities.

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

药物 / 成分：Rocatinlimab、Placebo

登记的停止原因（原文）：Sponsor Decision

Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy

药物 / 成分：GEN1055、Pembrolizumab、Standard Chemotherapy

登记的停止原因（原文）：Terminated due to strategic decision

An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

药物 / 成分：Batoclimab

登记的停止原因（原文）：Sponsor Decision

CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study

药物 / 成分：CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc、Placebo Administration

登记的停止原因（原文）：Terminated early by the Sponsor due to business reason.

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

药物 / 成分：SCY-078、Fluconazole、Echinocandin

登记的停止原因（原文）：Strategic decision not related to safety or efficacy concerns for Ibrexafungerp.

Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

药物 / 成分：MK-6194、Placebo

登记的停止原因（原文）：Business Reasons

A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis

药物 / 成分：ZL-1102 1% w/w gel BID for 16 weeks、ZL-1102 3% w/w gel BID for 16 weeks、ZL-1102 3% w/w gel QD for 16 weeks、Placebo ZL-1102 0% w/w gel BID for 16 weeks

登记的停止原因（原文）：Sponsor decision

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

药物 / 成分：Amlitelimab、Placebo

登记的停止原因（原文）：Sponsor decision; the decision is not related to any safety concern

A Study to Test How Different Doses of BI 3731579 Are Tolerated by Healthy People

药物 / 成分：Mid-dose bid BI 3731579、Placebo-matching BI 3731579、Midazolam、Low-dose bid BI 3731579

Evaluating Smoking Cessation Protocols in Cancer Patients: NRT, MI, CBT or Hypnotherapy

药物 / 成分：Motivational Interviewing (MI)、Cognitive Behavioural Therapy (CBT)、Hypnotherapy、Nicotine Replacement Therapy (NRT)

登记的停止原因（原文）：lack of patient enrolment

Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer

药物 / 成分：18F-Clofarabine

登记的停止原因（原文）：Funding unavailable

Evaluating Intra-articular Injection of Axolotl Ambient Compared to Saline in Subjects With Ankle Osteoarthritis

药物 / 成分：Axolotl Ambient、"Drug/Placebo: 0.9% Normal Saline"

登记的停止原因（原文）：This study was terminated by the Sponsor in December 2023 due to business considerations.

A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK

药物 / 成分：Pfs48/45 in Matrix-M

登记的停止原因（原文）：Significant delays in vaccine adjuvant supply due to an out of specification within the context of the grant timeline. Limited safety and immunological data could be accrued from incomplete regimens.

Diazoxide Suppression Test P&F Study

药物 / 成分：Diazoxide, 3 mg/kg per dose

登记的停止原因（原文）：Reprioritization of research efforts

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

药物 / 成分：ALXN2420、Placebo

登记的停止原因（原文）：This decision is based on strategic portfolio prioritization

Vitamin D Supplementation and the Immune Response

药物 / 成分：Vitamin D (drug)

High Dose IL-2 in Combination With Anti-PD-1

药物 / 成分：IL-2 and Nivolumab

登记的停止原因（原文）：Lack of funding